Enhancing safety of cytomegalovirus-based vaccine vectors by engaging host intrinsic immunity
- 17 July 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (501)
Abstract
Rhesus cytomegalovirus (RhCMV)–based vaccines maintain effector memory T cell responses (TEM) that protect ~50% of rhesus monkeys (RMs) challenged with simian immunodeficiency virus (SIV). Because human CMV (HCMV) causes disease in immunodeficient subjects, clinical translation will depend upon attenuation strategies that reduce pathogenic potential without sacrificing CMV’s unique immunological properties. We demonstrate that “intrinsic” immunity can be used to attenuate strain 68-1 RhCMV vectors without impairment of immunogenicity. The tegument proteins pp71 and UL35 encoded by UL82 and UL35 of HCMV counteract cell-intrinsic restriction via degradation of host transcriptional repressors. When the corresponding RhCMV genes, Rh110 and Rh59, were deleted from 68-1 RhCMV (ΔRh110 and ΔRh59), we observed only a modest growth defect in vitro, but in vivo, these modified vectors manifested little to no amplification at the injection site and dissemination to distant sites, in contrast to parental 68-1 RhCMV. ΔRh110 was not shed at any time after infection and was not transmitted to naïve hosts either by close contact (mother to infant) or by leukocyte transfusion. In contrast, ΔRh59 was both shed and transmitted by leukocyte transfusion, indicating less effective attenuation than pp71 deletion. The T cell immunogenicity of ΔRh110 was essentially identical to 68-1 RhCMV with respect to magnitude, TEM phenotype, epitope targeting, and durability. Thus, pp71 deletion preserves CMV vector immunogenicity while stringently limiting vector spread, making pp71 deletion an attractive attenuation strategy for HCMV vectors.Keywords
Funding Information
- NIH Office of the Director (P51 OD011092)
- National Institute of Allergy and Infectious Diseases (R01 AI095113)
- National Institute of Allergy and Infectious Diseases (P01 AI094417)
- National Institute of Allergy and Infectious Diseases (R37 AI054292)
- National Institute of Allergy and Infectious Diseases (R01 AI059457)
- National Institute of Allergy and Infectious Diseases (U42 OD023038)
- Bill and Melinda Gates Foundation (OPP1033121)
This publication has 79 references indexed in Scilit:
- Cytomegalovirus Vectors Violate CD8 + T Cell Epitope Recognition ParadigmsScience, 2013
- BclAF1 restriction factor is neutralized by proteasomal degradation and microRNA repression during human cytomegalovirus infectionProceedings of the National Academy of Sciences, 2012
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Evasion of CD8 + T Cells Is Critical for Superinfection by CytomegalovirusScience, 2010
- Cytomegalovirus Reinfections in Healthy Seroimmune WomenThe Journal of Infectious Diseases, 2010
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challengeNature Medicine, 2009
- Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell typesProceedings of the National Academy of Sciences, 2008
- Protein coding content of the ULb′ region of wild-type rhesus cytomegalovirusVirology, 2008
- Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infectionJournal of Experimental Medicine, 2007
- Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjectsJournal of Experimental Medicine, 2005